Can Auvelity and Cymbalta Be Prescribed Together?
Auvelity (dextromethorphan/bupropion) and Cymbalta (duloxetine) should NOT be prescribed together due to significant risk of serotonin syndrome from combining multiple serotonergic agents.
Critical Safety Concern: Serotonin Syndrome Risk
The primary contraindication stems from the dangerous combination of serotonergic medications. Caution must be exercised when combining two or more non-MAOI serotonergic drugs 1. Both medications in this combination have serotonergic activity:
- Dextromethorphan (component of Auvelity) is explicitly listed as a serotonergic cough/cold medication that requires caution when combined with other serotonergic drugs 1
- Duloxetine is an SNRI with direct serotonergic effects 1
- Bupropion (the other component of Auvelity) adds additional complexity through CYP2D6 inhibition 2
Understanding Serotonin Syndrome
Serotonin syndrome presents with a triad of symptoms 1:
- Mental status changes: confusion, agitation, anxiety
- Neuromuscular hyperactivity: tremors, clonus, hyperreflexia, muscle rigidity
- Autonomic hyperactivity: hypertension, tachycardia, arrhythmias, tachypnea, diaphoresis, shivering, vomiting, diarrhea
Advanced symptoms include fever, seizures, arrhythmias, and unconsciousness, which can be fatal. Symptoms typically arise within 24-48 hours after combining medications 1.
FDA Label Guidance
The Auvelity prescribing information specifically instructs patients to inform their healthcare provider of all medications they are taking, including other dextromethorphan-containing products 3. While the label doesn't explicitly list every contraindicated combination, the general warning about serotonergic medications applies 3.
Alternative Approaches
If a patient requires treatment optimization:
Option 1: Switch, Don't Combine
- Discontinue duloxetine completely before initiating Auvelity
- Allow appropriate washout period (at least 5 half-lives of duloxetine, approximately 5 days) 1
- Monitor closely during transition
Option 2: Augmentation with Non-Serotonergic Agents
If duloxetine provides partial benefit:
- Consider augmenting duloxetine with non-serotonergic options like lithium or atypical antipsychotics 4
- Bupropion alone (without dextromethorphan) combined with duloxetine has been studied with some success 5, 6, though this still requires careful monitoring
Option 3: Separate Component Administration
One case report describes using bupropion and dextromethorphan administered separately (not as Auvelity) 7, but this does not eliminate the serotonin syndrome risk and should only be considered with extreme caution and close monitoring.
Important Caveats
The combination of duloxetine and bupropion alone (without dextromethorphan) has been studied for treatment-resistant depression with mixed results 5, 6. However, adding dextromethorphan to this combination substantially increases serotonin syndrome risk and is not recommended.
Duloxetine is a moderate CYP2D6 inhibitor 1, which could theoretically affect dextromethorphan metabolism, though bupropion in Auvelity already serves this inhibitory function 3. This creates additional pharmacokinetic complexity beyond the pharmacodynamic serotonin concerns.
Clinical Bottom Line
Do not prescribe Auvelity and Cymbalta together. If treatment optimization is needed, choose one agent or the other, allow appropriate washout when switching, and monitor closely for emergence of serotonin syndrome symptoms, especially in the first 24-48 hours after any medication change 1.